VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company, has announced a proposed underwritten public offering of its common stock and accompanying common stock purchase warrants. The company also plans to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares and warrants offered at the public offering price. All securities will be offered by VolitionRx. Net proceeds from the offering are intended for research and product development, clinical studies, commercialization, working capital, and general corporate purposes, including potential strategic acquisitions. Newbridge Securities Corporation is acting as the sole book-running manager for the offering.